Alzheimer's disease (AD) is characterized by hallmark lesions such as amyloid rich senile plaques and neurofibrillary tangles. Amyloid beta (Abeta) peptides, which are derived from the proteolytic processing of one or more of the alternatively spliced Abeta precursor protein (APP) isoforms are the building blocks of the amyloid fibrils in the neuritic plaques that accumulate in the brains of patients with AD. The 2 major forms of Abeta in amyloid plaques terminate at amino acid 40 or 42/43 of this peptide, and brain cells secrete much high levels of Abeta/1-40 than Abeta/1-42. However, Abeta/1-42 is much less soluble than it aggregates far more readily than Abeta/1-40. Indeed, Abeta/1-42 predominates in the amyloid plaques that riddle the AD brain. Thus, the elucidation of intracellular pathways that lead to the production of Abeta particularly Abeta/1-42 in brain cells such as the neuron would increase our understanding of those mechanisms that underlie the pathogenesis of senile plaques in AD. During the last funding cycle of this Project, we identified the endoplasmic reticulum/intermediate compartment (ER/IC) as a novel site for the production of Abeta/1-42 but not Abeta/1-40 in human NT2N neurons. Significantly, some of the ER/IC produced Abeta/1-42 formed a stable, insoluble pool of intracellular Abeta that progressively accumulated as the NT2N neurons aged in culture. This aggregated intracellular Abeta/1-42 could compromise the survival of selectively vulnerable neurons. Thus, the studies proposed in this renewal application will test the hypothesis that perturbation of APP processing leading to progressive intracellular accumulation of Abeta particularly Abeta/1-42 in AD brains may lead to neuron death. To accomplish this, we will use reagents and tools that we have developed during the last funding cycle to dissect the different intracellular pathways that produce Abeta/1-40 and Abeta/1-42. We will determine whether or not Abeta/1-42, soluble intracellular Abeta/1-40 and Abeta/1-42 as well as insoluble, aggregated Abeta/1-40 and Abeta/1-42. Close collaboration with other investigators in the Program Project will allow us to determine how the production of the different pools of Abeta particularly intracellular Abeta/1-42 are regulated. These studies should also provide clues to the importance of intracellular Abeta in neuron death.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG011542-07
Application #
6201018
Study Section
Project Start
1999-09-01
Project End
2000-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Hurtado, David E; Molina-Porcel, Laura; Carroll, Jenna C et al. (2012) Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 32:7392-402
Hurtado, David E; Molina-Porcel, Laura; Iba, Michiyo et al. (2010) A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177:1977-88
Xu, Shaohua; Brunden, Kurt R; Trojanowski, John Q et al. (2010) Characterization of tau fibrillization in vitro. Alzheimers Dement 6:110-7
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Chen, Xiao-Han; Johnson, Victoria E; Uryu, Kunihiro et al. (2009) A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 19:214-23
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Shineman, Diana W; Dain, Aleksandra S; Kim, Minkyu L et al. (2009) Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 48:3787-94
Kim, Minkyu L; Zhang, Bin; Mills, Ian P et al. (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28:12052-61

Showing the most recent 10 out of 94 publications